Tags

Type your tag names separated by a space and hit enter

Use of i.v. immune globulin and occurrence of associated acute renal failure and thrombosis.
Am J Health Syst Pharm. 2005 Apr 01; 62(7):720-5.AJ

Abstract

PURPOSE

The use trends of i.v. immune globulin (IGIV) and the frequency of acute renal failure (ARF) and thrombosis at one institution were studied.

METHODS

A retrospective chart review on the indications and dosages of IGIV was conducted with inpatients and outpatients at a Veterans Affairs medical center between May 1, 1998, and June 30, 2003. Patients under 18 years of age were excluded from the study. Patient data were obtained through the center's computerized patient record system and included patient demographics, comorbidities, frequency of ARF, concomitant therapies, and IGIV therapy courses. ARF was defined as an increase in serum creatinine of >/=0.5 mg/dL within 10 days from the initiation of IGIV therapy.

RESULTS

Forty-six patients were identified as receiving at least one cycle of IGIV therapy between May 1, 1998, and June 30, 2003. The three main indications for IGIV therapy were hypogammaglobulinemia, idiopathic thrombocytopenic purpura (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). No new cases of thrombosis were found. Six patients (13%) developed ARF after IGIV administration, but none required dialysis. A greater percentage of patients with ARF were 65 years or older, had chronic renal insufficiency or diabetes mellitus, and used nephrotoxic agents, compared with patients who did not develop ARF. No association was observed between ARF and underlying primary disease.

CONCLUSION

A retrospective review of 46 courses of IGIV therapy showed that the therapy was most often used for hematologic, neurologic, and immunologic indications, and the most common diagnoses for which it was used were hypogammaglobulinemia, ITP, and CIDP. ARF developed in 13% of patients, but no case of thrombosis was reported.

Authors+Show Affiliations

School of Pharmacy, Texas Tech University, Dallas/Fort Worth, Dallas, TX 75216, USA. sachin.shah@ttuhsc.eduNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15790799

Citation

Shah, Sachin, and Marne Vervan. "Use of I.v. Immune Globulin and Occurrence of Associated Acute Renal Failure and Thrombosis." American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists, vol. 62, no. 7, 2005, pp. 720-5.
Shah S, Vervan M. Use of i.v. immune globulin and occurrence of associated acute renal failure and thrombosis. Am J Health Syst Pharm. 2005;62(7):720-5.
Shah, S., & Vervan, M. (2005). Use of i.v. immune globulin and occurrence of associated acute renal failure and thrombosis. American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists, 62(7), 720-5.
Shah S, Vervan M. Use of I.v. Immune Globulin and Occurrence of Associated Acute Renal Failure and Thrombosis. Am J Health Syst Pharm. 2005 Apr 1;62(7):720-5. PubMed PMID: 15790799.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of i.v. immune globulin and occurrence of associated acute renal failure and thrombosis. AU - Shah,Sachin, AU - Vervan,Marne, PY - 2005/3/26/pubmed PY - 2005/7/15/medline PY - 2005/3/26/entrez SP - 720 EP - 5 JF - American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists JO - Am J Health Syst Pharm VL - 62 IS - 7 N2 - PURPOSE: The use trends of i.v. immune globulin (IGIV) and the frequency of acute renal failure (ARF) and thrombosis at one institution were studied. METHODS: A retrospective chart review on the indications and dosages of IGIV was conducted with inpatients and outpatients at a Veterans Affairs medical center between May 1, 1998, and June 30, 2003. Patients under 18 years of age were excluded from the study. Patient data were obtained through the center's computerized patient record system and included patient demographics, comorbidities, frequency of ARF, concomitant therapies, and IGIV therapy courses. ARF was defined as an increase in serum creatinine of >/=0.5 mg/dL within 10 days from the initiation of IGIV therapy. RESULTS: Forty-six patients were identified as receiving at least one cycle of IGIV therapy between May 1, 1998, and June 30, 2003. The three main indications for IGIV therapy were hypogammaglobulinemia, idiopathic thrombocytopenic purpura (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). No new cases of thrombosis were found. Six patients (13%) developed ARF after IGIV administration, but none required dialysis. A greater percentage of patients with ARF were 65 years or older, had chronic renal insufficiency or diabetes mellitus, and used nephrotoxic agents, compared with patients who did not develop ARF. No association was observed between ARF and underlying primary disease. CONCLUSION: A retrospective review of 46 courses of IGIV therapy showed that the therapy was most often used for hematologic, neurologic, and immunologic indications, and the most common diagnoses for which it was used were hypogammaglobulinemia, ITP, and CIDP. ARF developed in 13% of patients, but no case of thrombosis was reported. SN - 1079-2082 UR - https://www.unboundmedicine.com/medline/citation/15790799/Use_of_i_v__immune_globulin_and_occurrence_of_associated_acute_renal_failure_and_thrombosis_ L2 - https://academic.oup.com/ajhp/article-lookup/doi/10.1093/ajhp/62.7.720 DB - PRIME DP - Unbound Medicine ER -